iMAC2MAC inhibitor CAS# 335166-36-4 |
2D Structure
- Celastrol
Catalog No.:BCN5986
CAS No.:34157-83-0
- BMS-345541
Catalog No.:BCC1423
CAS No.:547757-23-3
- Bay 65-1942 free base
Catalog No.:BCC1408
CAS No.:600734-02-9
- Bay 65-1942 HCl salt
Catalog No.:BCC1409
CAS No.:600734-06-3
- Bay 65-1942 R form
Catalog No.:BCC1410
CAS No.:758683-21-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 335166-36-4 | SDF | Download SDF |
PubChem ID | 9869276 | Appearance | Powder |
Formula | C19H20Br2FN3 | M.Wt | 469.2 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Limited solubility | ||
Chemical Name | 3,6-dibromo-9-(2-fluoro-3-piperazin-1-ylpropyl)carbazole | ||
SMILES | C1CN(CCN1)CC(CN2C3=C(C=C(C=C3)Br)C4=C2C=CC(=C4)Br)F | ||
Standard InChIKey | BSTYITXHUQTYBA-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H20Br2FN3/c20-13-1-3-18-16(9-13)17-10-14(21)2-4-19(17)25(18)12-15(22)11-24-7-5-23-6-8-24/h1-4,9-10,15,23H,5-8,11-12H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
iMAC2 Dilution Calculator
iMAC2 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1313 mL | 10.6564 mL | 21.3129 mL | 42.6257 mL | 53.2822 mL |
5 mM | 0.4263 mL | 2.1313 mL | 4.2626 mL | 8.5251 mL | 10.6564 mL |
10 mM | 0.2131 mL | 1.0656 mL | 2.1313 mL | 4.2626 mL | 5.3282 mL |
50 mM | 0.0426 mL | 0.2131 mL | 0.4263 mL | 0.8525 mL | 1.0656 mL |
100 mM | 0.0213 mL | 0.1066 mL | 0.2131 mL | 0.4263 mL | 0.5328 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Inhibitor of mitochondrial apoptosis-induced channel (MAC) (IC50 = 28 nM). Reduces STS-induced apoptosis in FL5.12 cells by over 50%. Inhibits release of cytochrome c by Bid-induced Bax activation (IC50 = 0.68 μM).
- Bax channel blocker
Catalog No.:BCC2392
CAS No.:335165-68-9
- 6'-Iodoresiniferatoxin
Catalog No.:BCC7114
CAS No.:335151-55-8
- Luteinizing Hormone Releasing Hormone (LHRH)
Catalog No.:BCC1049
CAS No.:33515-09-2
- Fucoxanthin
Catalog No.:BCN2948
CAS No.:3351-86-8
- Substance P
Catalog No.:BCC6957
CAS No.:33507-63-0
- MEK inhibitor
Catalog No.:BCC1738
CAS No.:334951-92-7
- (S)-HexylHIBO
Catalog No.:BCC7167
CAS No.:334887-48-8
- HexylHIBO
Catalog No.:BCC7166
CAS No.:334887-43-3
- Gisadenafil besylate
Catalog No.:BCC7871
CAS No.:334827-98-4
- Laburnine
Catalog No.:BCN1992
CAS No.:3348-73-0
- Tracheloside
Catalog No.:BCN2738
CAS No.:33464-71-0
- 3-Aminopiperidine dihydrochloride
Catalog No.:BCC8619
CAS No.:334618-23-4
- Raddeanoside 20
Catalog No.:BCN2796
CAS No.:335354-79-5
- Cyclo(Phe-Leu)
Catalog No.:BCN2418
CAS No.:3354-31-2
- (-)-Bilobalide
Catalog No.:BCN1279
CAS No.:33570-04-6
- Polpunonic acid
Catalog No.:BCN7136
CAS No.:33600-93-0
- Myricanol
Catalog No.:BCN5258
CAS No.:33606-81-4
- Ispinesib (SB-715992)
Catalog No.:BCC2509
CAS No.:336113-53-2
- Britannilactone
Catalog No.:BCN3509
CAS No.:33620-72-3
- Desoxyrhapontigenin
Catalog No.:BCN6479
CAS No.:33626-08-3
- Britannin
Catalog No.:BCN2366
CAS No.:33627-28-0
- 1-O-Acetylbritannilactone
Catalog No.:BCN7715
CAS No.:33627-41-7
- (S)-(+)-Ketamine hydrochloride
Catalog No.:BCC7930
CAS No.:33643-47-9
- H-Thr-Obzl.HCl
Catalog No.:BCC2674
CAS No.:33645-24-8
Implantable cardiac defibrillators and sudden death in recent onset nonischemic cardiomyopathy: results from IMAC2.[Pubmed:22939035]
J Card Fail. 2012 Sep;18(9):675-81.
BACKGROUND: Given the potential for recovery in recent onset nonischemic cardiomyopathy (ROCM), the timing and need for implantable cardioverter-defibrillator (ICDs) remains controversial. We examined the utilization of ICDs and the impact on survival for subjects with ROCM. METHODS AND RESULTS: An National Heart, Lung, and Blood Institute sponsored registry enrolled 373 subjects with ROCM, all with a left ventricular ejection fraction (LVEF) =0.40 and =6 months of symptoms. The mean age was 45 +/- 14 years, 38% were female, 21% black, 75% New York Heart Association II/III, and the mean LVEF was 0.24 +/- 0.08. Survival was comparable for subjects with an ICD within 1 month of entry (n = 43, 1/2/3 year % survival = 97/97/92) and those with no ICD at 1 month (n = 330, % survival = 98/97/95, P = .30) and between those with and without an ICD at 6 months (ICD, n = 73, 1/2/3 year % survival = 98/98/95; no ICD, n = 300, % survival = 98/96/95, P = .95). There were only 6 sudden cardiac deaths (SCD) noted (% survival free from SCD = 99/98/97) and these occurred in 1.9% of subjects without ICD and 0.9% of those with a device (P = .50). CONCLUSIONS: In a multicenter cohort of ROCM the risk of SCD was low at 1% per year. Early ICD placement did not impact survival and can be deferred while assessing potential for myocardial recovery.